Epithelial Ovarian Cancer

Epithelial ovarian cancer is the most common type of ovarian malignancy, representing over 95% of cases, while non-epithelial ovarian cancers, including germ cell, sex-cord stromal, and small cell ovarian cancers, account for approximately 5%.

References:

[1]. Michelle A Roett, et al. Ovarian cancer: an overview. Review Am Fam Physician. 2009 Sep 15;80(6):609-16.

Epithelial Ovarian Cancer (3):

Targets:	Angiotensin-converting Enzyme (ACE) (2) SARS-CoV (2) PD-1/PD-L1 (1) Proteasome (1)

Cat. No.	Product Name	CAS No.	Purity	Chemical Structure

HY-P5407

HD5	798569-33-2
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.

HY-P5407A

HD5 TFA
HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.

HY-180127

UR238	2728747-80-4
UR238 is a proteasome inhibitor. UR238 reduces levels of the immunomodulator HE4. UR238 decreases PDL1 expression on cells. UR238 exhibits anticancer activity against epithelial ovarian cancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.